Cerulean to Present at JMP Securities Life Sciences Conference

WALTHAM, Mass.--()--Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Christopher D. T. Guiffre, President & Chief Executive Officer, will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, June 21 at 1:30 p.m. ET.

A live audio webcast of the presentation will be available on the “Investors” section of the Company’s website, www.ceruleanrx.com with the replay available for two weeks following the presentation.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated NDC clinical candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit www.ceruleanrx.com.

Contacts

Cerulean Pharma
Nicole P. Jones, 781-209-6385
Director, Investor Relations and Corporate Communications
njones@ceruleanrx.com

Contacts

Cerulean Pharma
Nicole P. Jones, 781-209-6385
Director, Investor Relations and Corporate Communications
njones@ceruleanrx.com